When biosimilars launch, the dynamics that will play out in a given therapy area or geography are highly uncertain. Given that biosimilars represent an entirely new product category—one with just a handful of early examples to date—the challenges to the forecaster are unique and formidable. The challenges apply equally to those tasked with forecasting biosimilar uptake or originator erosion.


In this white paper, Stephen Lamb and Art Cook weigh in on these challenges, assess the dynamics at play in the market at various points in the forecast funnel, and share their thoughts on the future of biosimilar forecasting.